Answers are grounded in this paper and cite their sources.
Background: South Africas 2023 revised ART Guidelines moved the first scheduled viral load (VL) test from 6 to 3 months after antiretroviral therapy (ART) initiation and accelerated differentiated care eligibility from 7 to 4 months among virally suppressed clients. We assessed uptake of these changes and their association with virologic outcomes. Methods: We analysed routine electronic medical record data from 18 primary healthcare clinics in three South African districts among all adults initiating or re-initiating ART (N=16,338; January 2022-March 2025). Interrupted time series analyses were used to assess uptake of 3-month VL testing and assignment to greater than or equal to 6-month visit intervals following guideline implementation in April 2023. Modified Poisson regression was used to compare relative risks (RRs) for viral suppression at the first and second routine VL tests among clients tested at 3 months (test window=56-111 days) and 6 months (112-<252 days). Results: At the first VL assessment, 27% of participants had VL tests at 3 months and 30% at 6 months; the rest had tests outside either window (19%) or no test documented (25%). Three-month VL testing rose immediately after guideline implementation, reaching 72-85% coverage by the end of the study period. Assignment to greater than or equal to 6month visit intervals among clients with 3-month viral suppression increased after implementation, reaching 48-71% across districts. A second VL result was documented for 62% of clients tested in the 3- or 6-month window. Viral suppression did not differ meaningfully between clients initially tested at 3 months (72%) and those initially tested at 6 months (72%). Among clients with a second scheduled VL result, 82% were virally suppressed. Assignment to greater than or equal to 6-month visit intervals was not associated with subsequent viral suppression (aRR 1.02, 95% CI 0.99-1.06). Results should be interpreted with caution due to missing VL data. Conclusion: South Africas 2023 guideline revision was associated with rapid increases in 3-month VL testing and assignment to longer visit intervals. Viral suppression at the first VL test was similar among clients tested at 3 and 6 months, and longer visit intervals were not associated with poorer outcomes. These findings support earlier differentiation of HIV care within routine service delivery. Incomplete uptake of recommended testing and visit intervals offers opportunities to strengthen implementation and warrants continued evaluation of longer-term outcomes.
No takes yet. Share an insight, caveat, or question.
Kachingwe et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: